ื‘ืจื–ืœ - ื”ืžื™ื ืจืœ ื”ื—ื™ื•ื ื™ ืœืื ืจื’ื™ื” ื•ืœืžื ื™ืขืช ืขื™ื™ืคื•ืช | ื”ืžื“ืจื™ืš ื”ืžืœื

ย 

ื‘ืจื–ืœ ื‘ื™ืกื’ืœื™ืฆื™ื ืื˜ + ื•ื™ื˜ืžื™ืŸ C + ืกืœื ื™ื•ื - ืคื•ืจืžื•ืœื” ืขื“ื™ื ื” ืœืื ืจื’ื™ื” ื™ื•ืžื™ื•ืžื™ืช

ื‘ืงืฆืจื”: ื‘ืจื–ืœ ื”ื•ื ืžื™ื ืจืœ ื—ืฉื•ื‘ ืœื™ื™ืฆื•ืจ ื”ืžื•ื’ืœื•ื‘ื™ืŸ,ื”ื ื—ืงืจ ื‘ื”ืงืฉืจ ืฉืœ ื”ืขื‘ืจืช ื—ืžืฆืŸ ื‘ื’ื•ืฃ ื•ืœืื ืจื’ื™ื” ื™ื•ืžื™ื•ืžื™ืช. ื—ืกืจ ื‘ื‘ืจื–ืœ - ื’ื ืœืœื ืื ืžื™ื” - ืขืฉื•ื™ ืœื”ืชื‘ื˜ื ื‘ืขื™ื™ืคื•ืช, ืงืฉื™ื™ ืจื™ื›ื•ื– ื•ืชื—ื•ืฉืช ื›ื‘ื“ื•ืช. ื‘ืจื–ืœ ื‘ื™ืกื’ืœื™ืฆื™ื ืื˜ ื”ื•ื ื”ืฆื•ืจื” ื”ื ืกื‘ืœืช ื‘ื™ื•ืชืจ ืขื ืกืคื™ื’ื” ื’ื‘ื•ื”ื”.

ืžื” ื–ื” ื‘ืจื–ืœ ื•ืžื” ืชืคืงื™ื“ื• ื‘ื’ื•ืฃ?

ื‘ืจื–ืœ ื”ื•ื ืžื™ื ืจืœ ื—ื™ื•ื ื™ ื”ืžืฉืชืชืฃ ื‘ืชื”ืœื™ื›ื™ื ืžืจื›ื–ื™ื™ื ื‘ื’ื•ืฃ:

  • ื™ื™ืฆื•ืจ ื”ืžื•ื’ืœื•ื‘ื™ืŸ - ื”ื—ืœื‘ื•ืŸ ืฉื ื•ืฉื ื—ืžืฆืŸ ื‘ื›ื“ื•ืจื™ื•ืช ื”ื“ื ื”ืื“ื•ืžื•ืช
  • ื™ื™ืฆื•ืจ ืžื™ื•ื’ืœื•ื‘ื™ืŸ - ืื—ืกื•ืŸ ื—ืžืฆืŸ ื‘ืชืื™ ืฉืจื™ืจ
  • ืชืคืงื•ื“ ืžื™ื˜ื•ื›ื•ื ื“ืจื™ืืœื™ - ื™ื™ืฆื•ืจ ืื ืจื’ื™ื” ื‘ืจืžืช ื”ืชื (ATP)
  • ืคืขื™ืœื•ืช ืื ื–ื™ืžื˜ื™ืช - ืžืขื•ืจื‘ ื‘-200+ ืชื”ืœื™ื›ื™ื ื‘ื™ื•ื›ื™ืžื™ื™ื
  • ืชืคืงื•ื“ ืžืขืจื›ืช ื”ื—ื™ืกื•ืŸ - ืชืžื™ื›ื” ื‘ืคืขื™ืœื•ืช ืชืื™ ื—ื™ืกื•ืŸ

ื—ืกืจ ื‘ืจื–ืœ - ื’ื ืœืœื ืื ืžื™ื”

ื”ื ืงื•ื“ื” ืฉืจื‘ื™ื ืžืคืกืคืกื™ื: ืืคืฉืจ ืœืกื‘ื•ืœ ืžื—ืกืจ ื‘ืจื–ืœ ื‘ืœื™ ืœื”ื™ื•ืช ืื ืžื™. ืžื” ืฉื ืงืจื Non-Anemic Iron Deficiency (NAID) - ืจืžืช ืคืจื™ื˜ื™ืŸ ื ืžื•ื›ื” ืขื ื”ืžื•ื’ืœื•ื‘ื™ืŸ ืชืงื™ืŸ - ืขืฉื•ื™ ืœื”ืชื‘ื˜ื ื‘ืชืกืžื™ื ื™ื ืžืฉืžืขื•ืชื™ื™ื.

๐Ÿ”ฌ Sultana et al., 2026 (JPMA - PMID: 41736325)

ืžื—ืงืจ ื›ืคื•ืœ-ืกืžื™ื•ืช ืฉื‘ื—ืŸ 164 ื ืฉื™ื ื‘ื’ื™ืœ ื”ืคื•ืจื™ื•ืช ืขื ื—ืกืจ ื‘ืจื–ืœ ืœืœื ืื ืžื™ื” (ื”ืžื•ื’ืœื•ื‘ื™ืŸ ืชืงื™ืŸ, ืคืจื™ื˜ื™ืŸ ื ืžื•ืš). ืœืื—ืจ 2 ื—ื•ื“ืฉื™ ื˜ื™ืคื•ืœ:

  • ื™ืจื™ื“ื” ืžื•ื‘ื”ืงืช ื‘ืฆื™ื•ืŸ ื”ืขื™ื™ืคื•ืช (p=0.05) ื‘ืงื‘ื•ืฆืช ื”ื‘ืจื–ืœ ืœืขื•ืžืช ืคืœืฆื‘ื•
  • ืขืœื™ื™ื” ืžืฉืžืขื•ืชื™ืช ื‘ืจืžื•ืช ื”ืคืจื™ื˜ื™ืŸ
  • ืฉื™ืคื•ืจ ื‘ืจืžื•ืช ื”ืžื•ื’ืœื•ื‘ื™ืŸ

PubMed PMID: 41736325

๐Ÿ”ฌ Thamotharan et al., 2025 (Cureus - PMID: 41607990)

ืžื—ืงืจ ืขืœ 100 ื ืฉื™ื ืžืฆื ืฉืจืžื•ืช ืคืจื™ื˜ื™ืŸ ื ืžื•ื›ื•ืช ืงืฉื•ืจื•ืช ืœืชืกืžื™ื ื™ื ืคื™ื–ื™ื™ื ืžื•ื‘ื”ืงื™ื, ื’ื ื›ืฉืื™ืŸ ืื ืžื™ื” ืงืœื™ื ื™ืช. ืžืžื•ืฆืข ืคืจื™ื˜ื™ืŸ ื‘ืงื‘ื•ืฆื” ื”ืกื™ืžืคื˜ื•ืžื˜ื™ืช: 24.30 ng/mL ืœืขื•ืžืช 44.78 ื‘ืงื‘ื•ืฆืช ื‘ื™ืงื•ืจืช (p<0.001).

PubMed PMID: 41607990

ืžื” ืžื™ื™ื—ื“ ื‘ืจื–ืœ ื‘ื™ืกื’ืœื™ืฆื™ื ืื˜?

ืœื ื›ืœ ื‘ืจื–ืœ ืฉื•ื•ื”. ื”ืฆื•ืจื” ืงื•ื‘ืขืช ืืช ื”ืกืคื™ื’ื” ื•ืืช ื”ื ื•ื—ื•ืช:

ืฆื•ืจืช ื‘ืจื–ืœ ืกืคื™ื’ื” ืชื•ืคืขื•ืช ืœื•ื•ืื™
ืคืจื•ืก ืกื•ืœืคื˜ ื‘ื™ื ื•ื ื™ืช-ื’ื‘ื•ื”ื” ืขืฆื™ืจื•ืช, ื‘ื—ื™ืœื” - ื ืคื•ืฅ
ื‘ื™ืกื’ืœื™ืฆื™ื ืื˜ ื’ื‘ื•ื”ื” ืžื™ื ื™ืžืœื™ - ื”ืฆื•ืจื” ื”ื ืกื‘ืœืช ื‘ื™ื•ืชืจ
ืคืจื•ืก ื’ืœื•ืงื•ื ืื˜ ื‘ื™ื ื•ื ื™ืช ืงืœื•ืช
ืคืจื™ืง Fe3+ ื ืžื•ื›ื” ื’ื‘ื•ื”ื•ืช ื™ื—ืกื™ืช

ื‘ืจื–ืœ ื‘ื™ืกื’ืœื™ืฆื™ื ืื˜ย  ื”ื•ื ื‘ืจื–ืœ ื”ืงืฉื•ืจ ืœืฉืชื™ ืžื•ืœืงื•ืœื•ืช ื’ืœื™ืฆื™ืŸ - ื—ื•ืžืฆืช ืืžื™ื ื•. ื”ืงืฉื™ืจื” ื”ื–ื•:

  • ืžื’ื™ื ื” ืขืœ ื”ื‘ืจื–ืœ ื‘ืกื‘ื™ื‘ื” ื”ื—ื•ืžืฆื™ืช ืฉืœ ื”ืงื™ื‘ื”
  • ืžืืคืฉืจืช ืกืคื™ื’ื” ื“ืจืš ื ืชื™ื‘ ืฉื•ื ื” ื•ื™ืขื™ืœ ื™ื•ืชืจ
  • ืžืคื—ื™ืชื” ื’ื™ืจื•ื™ ืฉืœ ื“ื•ืคืŸ ื”ืงื™ื‘ื”
  • ืžืชืื™ื ืœื™ื˜ื•ืœ ื’ื ืขื ืื•ื›ืœ

ื”ืกื™ื ืจื’ื™ื”: ื‘ืจื–ืœ + ื•ื™ื˜ืžื™ืŸ C + ืกืœื ื™ื•ื

ื•ื™ื˜ืžื™ืŸ C - ืžื’ื‘ืจ ื”ืกืคื™ื’ื”

ื•ื™ื˜ืžื™ืŸ C (ื—ื•ืžืฆื” ืืกืงื•ืจื‘ื™ืช) ืžืžื™ืจ ื‘ืจื–ืœ ืคืจื™ืง (Fe3+) ืœื‘ืจื–ืœ ืคืจื™ (Fe2+) - ื”ืฆื•ืจื” ื”ื ืกืคื’ืช. ื ื˜ื™ืœื” ืžืฉื•ืœื‘ืช ืขืฉื•ื™ื” ืœื”ื’ื“ื™ืœ ืกืคื™ื’ืช ื‘ืจื–ืœ ื‘ืฆื•ืจื” ืžืฉืžืขื•ืชื™ืช, ื‘ืžื™ื•ื—ื“ ื‘ืชื–ื•ื ื” ืฆืžื—ื™ืช.

ืกืœื ื™ื•ื - ื ื•ื’ื“ ื—ืžืฆื•ืŸ ืžื’ืŸ

ืกืœื ื™ื•ื ื”ื•ื ืžืจื›ื™ื‘ ืงืจื™ื˜ื™ ื‘ืื ื–ื™ื Glutathione Peroxidase - ืžืขืจื›ืช ื”ื”ื’ื ื” ื ื’ื“ ื ื–ืง ื—ืžืฆื•ื ื™ ื‘ื’ื•ืฃ. ืชืคืงื™ื“ื™ื•:

  • ืชืžื™ื›ื” ื‘ืชืคืงื•ื“ ืชืงื™ืŸ ืฉืœ ื‘ืœื•ื˜ืช ื”ืชืจื™ืก (ื”ืžื•ื•ืกืช ืื ืจื’ื™ื”)
  • ืคืขื™ืœื•ืช ื ื•ื’ื“ืช ื—ืžืฆื•ืŸ
  • ืชืžื™ื›ื” ื‘ืžืขืจื›ืช ื”ื—ื™ืกื•ืŸ

ืžื™ ืขืฉื•ื™ ืœื”ืคื™ืง ืชื•ืขืœืช ืžืชื•ืกืฃ ื‘ืจื–ืœ?

  • ๐Ÿฉธ ื ืฉื™ื ื‘ื’ื™ืœ ื”ืคื•ืจื™ื•ืช - ืื•ื‘ื“ืŸ ื‘ืจื–ืœ ืงื‘ื•ืข ื‘ื›ืœ ืžื—ื–ื•ืจ
  • ๐Ÿคฐ ื ืฉื™ื ื‘ื”ืจื™ื•ืŸ ื•ืœืื—ืจ ืœื™ื“ื” - ื‘ื™ืงื•ืฉ ืžื•ื’ื‘ืจ ืœื‘ืจื–ืœ
  • ๐Ÿฅ— ืฆืžื—ื•ื ื™ื ื•ื˜ื‘ืขื•ื ื™ื - ื‘ืจื–ืœ ืžื”ืฆื•ืžื— ื ืกืคื’ ืคื—ื•ืช (2-20% ืœืขื•ืžืช 15-35% ืžื”ื—ื™)
  • ๐Ÿƒ ืกืคื•ืจื˜ืื™ื•ืช - ื”ืžื•ืœื™ื–ื” ืžืคืขื™ืœื•ืช ื’ื•ืคื ื™ืช ืื™ื ื˜ื ืกื™ื‘ื™ืช
  • ๐Ÿ˜ด ืžื™ ืฉืกื•ื‘ืœ ืžืขื™ื™ืคื•ืช ื›ืจื•ื ื™ืช ืœืœื ื”ืกื‘ืจ ื‘ืจื•ืจ
ื—ืฉื•ื‘: ืœืคื ื™ ื ื˜ื™ืœืช ืชื•ืกืฃ ื‘ืจื–ืœ - ืžื•ืžืœืฅ ืœื‘ืฆืข ื‘ื“ื™ืงืช ื“ื ื”ื›ื•ืœืœืช ืคืจื™ื˜ื™ืŸ (ืœื ืจืง ื”ืžื•ื’ืœื•ื‘ื™ืŸ). ืขื•ื“ืฃ ื‘ืจื–ืœ ืžืกื•ื›ืŸ. ืชื•ืกืฃ ื‘ืจื–ืœ ืœืœื ืื™ื ื“ื™ืงืฆื™ื” ืื™ื ื• ืžื•ืžืœืฅ.

ืฉืืœื•ืช ื ืคื•ืฆื•ืช

ืžืชื™ ื›ื“ืื™ ืœืงื—ืช ื‘ืจื–ืœ?

ื‘ืจื–ืœ ื‘ื™ืกื’ืœื™ืฆื™ื ืื˜ ื ื™ืชืŸ ืœื ื˜ื•ืœ ืขื ืืจื•ื—ื” ืื• ื‘ืœืขื“ื™ื”. ืื ื™ืฉ ืจื’ื™ืฉื•ืช - ืขื ืื•ื›ืœ. ืขื“ื™ืฃ ืœื”ื™ืžื ืข ืžื ื˜ื™ืœื” ื™ื—ื“ ืขื ืงืคื”, ืชื” ืื• ืžื•ืฆืจื™ ื—ืœื‘ ืฉืขืœื•ืœื™ื ืœื”ืคืจื™ืข ืœืกืคื™ื’ื”.

ื›ืžื” ื–ืžืŸ ืขื“ ืœืชื•ืฆืื•ืช?

ืœืจื•ื‘ ืื ืฉื™ื ืžื“ื•ื•ื—ื™ื ืขืœ ืขืœื™ื™ื” ื‘ืจืžื•ืช ืคืจื™ื˜ื™ืŸ ืžื•ืจื’ืฉืช ืชื•ืš 4-8 ืฉื‘ื•ืขื•ืช. ืฉื™ืคื•ืจ ื‘ืชื—ื•ืฉืช ื”ืื ืจื’ื™ื” ืขืฉื•ื™ ืœื”ื™ื•ืช ืžื•ืจื’ืฉ ืชื•ืš 2-4 ืฉื‘ื•ืขื•ืช ื‘ื—ืกืจ ืžืฉืžืขื•ืชื™.

ื”ืื ื‘ืจื–ืœ ืžืชืื™ื ืœื’ื‘ืจื™ื?

ื’ื‘ืจื™ื ื‘ืจื™ืื™ื ื ื–ืงืงื™ื ืœื›ืžื•ืช ื‘ืจื–ืœ ืงื˜ื ื” ื™ื•ืชืจ ื•ืื™ื ื ืžืื‘ื“ื™ื ื‘ืจื–ืœ ื‘ืžื—ื–ื•ืจ. ืขื ื–ืืช, ืกืคื•ืจื˜ืื™ื, ื˜ื‘ืขื•ื ื™ื ื•ืฆืžื—ื•ื ื™ื ื’ื‘ืจื™ื ืขืฉื•ื™ื™ื ืœื”ื–ื“ืงืง ืœืชื•ืกืฃ. ืžื•ืžืœืฅ ืœื‘ื“ื•ืง ืจืžื•ืช ืœืคื ื™ ื ื˜ื™ืœื”.

ื‘ืจื–ืœ ื‘ื™ืกื’ืœื™ืฆื™ื ืื˜ ืฉืœ Harmony

ืคื•ืจืžื•ืœื” ืขื“ื™ื ื” ื”ืžื›ื™ืœื” 36 ืž"ื’ ื‘ืจื–ืœ ื‘ื™ืกื’ืœื™ืฆื™ื ืื˜ + ื•ื™ื˜ืžื™ืŸ C ืœืกืคื™ื’ื” ืžื™ื˜ื‘ื™ืช + ืกืœื ื™ื•ื ืœืชืžื™ื›ื” ื ื•ื’ื“ืช ื—ืžืฆื•ืŸ. ืœืœื ืชื•ืคืขื•ืช ืœื•ื•ืื™ ืงืฉื•ืช, ืžืชืื™ื ืœื ื˜ื™ืœื” ื™ื•ืžื™ื•ืžื™ืช.

ืœืคืจื˜ื™ื ืขืœ ืชื•ืกืฃ ื”ื‘ืจื–ืœ โ†’

* ื”ืžื™ื“ืข ื‘ืืชืจ ื–ื” ื”ื•ื ืœืžื˜ืจื•ืช ืžื™ื“ืข ื‘ืœื‘ื“ ื•ืื™ื ื• ืžื”ื•ื•ื” ื™ื™ืขื•ืฅ ืจืคื•ืื™. ืชื•ืกืคื™ ืชื–ื•ื ื” ืื™ื ื ืชืจื•ืคื•ืช ื•ืื™ื ื ืžื™ื•ืขื“ื™ื ืœืื‘ื—ืŸ, ืœืจืคื ืื• ืœืžื ื•ืข ืžื—ืœื”. ืคื ื” ืœืจื•ืคื ืœืคื ื™ ื ื˜ื™ืœืช ืชื•ืกืคื™ ื‘ืจื–ืœ.